Orchestra BioMed Holdings (NASDAQ: OBIO) reported a second-quarter net loss attributable to common stockholders of $24.1 million, or $(0.38) per share, for the period ended June 30, 2026. The loss widened 23 percent from $19.4 million in the same quarter of the prior year, primarily due to increased research and development expenses associated with its pivotal clinical trials. Despite the operational losses, the company bolstered its balance sheet by receiving $35 million in strategic capital from partners Medtronic and Ligand, bringing its total cash and marketable securities to $110 million as of June 30, 2026. This liquidity position provides a projected runway into the fourth quarter of 2027, covering key upcoming milestones for its two flagship programs.

The financial performance reflects a strategic shift toward accelerated clinical development rather than near-term revenue generation. Total revenue fell to $88,000 from $836,000 in Q2 2025, an 89 percent decline, as partnership revenue dropped to zero and product revenue decreased to $88,000 from $169,000. Research and development expenses rose 20 percent year-over-year to $16.6 million, driven by costs related to the BACKBEAT trial and the Virtue SAB program. Conversely, selling, general, and administrative expenses declined 7 percent to $5.8 million, aided by reduced stock-based compensation. The divergence between collapsing revenue and rising R&D spend underscores the company’s pre-commercial stage focus on regulatory approvals.

Clinical and Strategic Milestones

Orchestra BioMed advanced its two primary cardiovascular programs during the quarter. The BACKBEAT global pivotal trial, conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by the end of Q3 2026. Assuming primary endpoints are met, the company intends to present primary data at a major cardiovascular conference in Q2 2027. Additionally, the FDA granted AVIM Therapy a second Breakthrough Device Designation, specifically for patients with uncontrolled hypertension who are indicated for a pacemaker. This complements the existing designation for broader uncontrolled hypertension cases.

Simultaneously, the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) program progressed with further site activations and patient enrollments in its pivotal trial for coronary in-stent restenosis. The capital infusion from Medtronic, which has now contributed nearly $82 million in total, and Ligand, which has provided $40 million, ensures funding through these critical phases. Orchestra BioMed also joined the Russell 3000 and Russell 2000 indexes effective June 26, 2026, enhancing visibility among institutional investors.

What the Numbers Show

The financial data reveals a classic biotech burn-rate dynamic where operational losses expand as clinical trials scale, even as management optimizes administrative costs. While revenue effectively vanished, indicating no significant commercial sales or partnership milestones were triggered in this quarter, the strategic capital inflow mitigates immediate liquidity concerns. The $110 million cash balance is robust relative to the quarterly net cash used in operating activities of $19.6 million. However, the widening net loss, partly fueled by $2.7 million in interest expense compared to $0.5 million last year, highlights the cost of debt instruments like the royalty purchase agreement and notes payable. Investors should monitor whether the upcoming Q3 2026 trial completion and Q2 2027 data readout can justify the current capital expenditure trajectory before the runway extends further.

Orchestra BioMed Holdings, Inc. has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, effective after the U.S. market close on June 26, 2026. The inclusion follows the conclusion of the 2026 Russell indexes reconstitution, which ranks the 4,000 largest U.S. stocks by total market capitalization as of April 30. Membership in the Russell 3000 ensures automatic inclusion in the Russell 2000 as well as the appropriate growth and value style indexes until the next semi-annual reconstitution.

The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.2 trillion in assets are benchmarked against Russell's U.S. indexes. FTSE Russell, a leading global index provider, determines membership primarily by objective, market-capitalization rankings and style attributes.

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The company's flagship product candidates include Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), both undergoing pivotal clinical trials.

AVIM Therapy, a bioelectronic treatment for hypertension, is delivered by a pacemaker and designed to achieve substantial reductions in blood pressure. The company has a strategic collaboration with Medtronic for the development and commercialization of AVIM Therapy. Virtue SAB is a non-coated drug delivery angioplasty balloon system designed to treat atherosclerotic artery disease. Both therapies have received FDA Breakthrough Device Designations.

FTSE Russell, wholly owned by London Stock Exchange Group, provides benchmarking, analytics, and data solutions for investors worldwide. The index provider calculates thousands of indexes covering 98% of the investable market globally. Its methodologies are guided by transparent rules-based principles informed by independent committees of leading market participants.